<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6183">
  <stage>Registered</stage>
  <submitdate>21/02/2013</submitdate>
  <approvaldate>21/02/2013</approvaldate>
  <nctid>NCT01802788</nctid>
  <trial_identification>
    <studytitle>5 Year Observation of Patients With PORTICO Valves</studytitle>
    <scientifictitle>International Long-term Follow-up Study of Patients Implanted With a Portico Valve</scientifictitle>
    <utrn />
    <trialacronym>PORTICO-1</trialacronym>
    <secondaryid>CV-12-054-EU-PV</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Aortic Valve Stenosis</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - St Jude Medical Portico replacement aortic valve
Treatment: surgery - Transcatheter Aortic Valve Implant

Cohort A - Patients implanted with a Portico valve bearing the CE mark (implanted after St Jude Medical declared the device "compliant" with all applicable essential requirements within the European union and marketed the device bearing the CE mark.)

Cohort B - Patients implanted with a Portico valve as part of an Investigational Device study.


Treatment: devices: St Jude Medical Portico replacement aortic valve


Treatment: surgery: Transcatheter Aortic Valve Implant


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>All-cause Mortality</outcome>
      <timepoint>1 year</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>All Cause Mortality</outcome>
      <timepoint>30 days, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years post device implant.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Frequency of Cardiovascular Mortality as defined by the Valve Academic Research Consortium (VARC) - Any one of the following criteria:
Death due to proximate cardiac cause (e.g., myocardial infarction, cardiac tamponade, worsening heart failure).
Death caused by non-coronary vascular conditions such as neurological events, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular disease.
All procedure-related deaths, including those related to a complication of the procedure or treatment for a complication of the procedure.
All valve-related deaths including structural or non-structural valve dysfunction or other valve-related adverse event.
Sudden or witnessed death.
Death of unknown cause.</outcome>
      <timepoint>30 days, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years post device implant.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Frequency of Myocardial Infarction as defined by VARC - Please refer to the following publication for a detailed description of this and all further VARC defined endpoints:
Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: The Valve Academic Research Consortium-2 consensus document. The Journal of Thoracic and Cardiovascular Surgery 2013;145(1):6-23.</outcome>
      <timepoint>30 days, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years post device implant.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Frequency of Stroke as defined by VARC.</outcome>
      <timepoint>30 days, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years post device implant.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Frequency of Bleeding events as defined by VARC.</outcome>
      <timepoint>30 days, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years post device implant.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Frequency of Acute Kidney injury as defined by VARC</outcome>
      <timepoint>30 days, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years post device implant.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Frequency of Vascular and access related complications as defined by VARC</outcome>
      <timepoint>30 days, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years post device implant.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Frequency of Conduction disturbances and cardiac arrythmias as defined by VARC. - In particular this includes the rate of pacemaker implantation at 30 days post procedure</outcome>
      <timepoint>30 days, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years post device implant.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Frequency of other TAVI related complications as defined by VARC. - Conversion to open surgery
Unplanned use of cardiopulmonary bypass (CPB)
Coronary obstruction
Ventricular septal perforation
Mitral valve apparatus damage or dysfunction
Cardiac tamponade
Endocarditis
Valve thrombosis
Valve malpositioning
Transcatheter valve in Transcatheter valve deployment</outcome>
      <timepoint>30 days, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years post device implant.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Prosthetic valve function as defined by VARC - Prosthetic valve stenosis
Prosthetic valve regurgitation</outcome>
      <timepoint>30 days, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years post device implant.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>VARC defined "device success" composite endpoint - Absence of procedural mortality AND
Correct positioning of a single prosthetic heart valve into the proper anatomical location AND
Intended performance of the prosthetic heart valve (no prosthesis-patient mismatch and mean aortic valve gradient &lt;20 mmHg or peak velocity &lt;3 m/s, AND no moderate or severe prosthetic valve regurgitation)</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>VARC defined "Early Safety" composite endpoint - All-cause mortality
All stroke (disabling and non-disabling)
Life-threatening bleeding
Acute kidney injuryStage 2 or 3 (including renal replacement therapy)
Coronary artery obstruction requiring intervention
Major vascular complication
Valve-related dysfunction requiring repeat procedure (Balloon Aortic Valvuloplasty (BAV), Trans Catheter Aortic Valve Implant (TAVI), or Surgical Aortic Valve Replacement (SAVR))</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>VARC defined "Clinical Efficacy" composite endpoint - All-cause mortality
All stroke (disabling and non-disabling)
Requiring hospitalizations for valve-related symptoms or worsening congestive heart failure
NYHA (New york Heart Association) class III or IV functional classification of heart failure.
Valve-related dysfunction (mean aortic valve gradient =20 mmHg, Effective Orifice Area (EOA) =0.9-1.1 cm2(c) and/or Doppler Velocity Integral (DVI) &lt;0. 35 m/s, AND/OR moderate or severe prosthetic valve regurgitation.</outcome>
      <timepoint>From 30 days post procedure to completion of follow up at 5 years.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>VARC defined "Time-related valve safety" composite endpoint - Structural valve deterioration
Valve-related dysfunction (mean aortic valve gradient
=20 mmHg, EOA =0.9-1.1 cm2cand/or DVI &lt;0.35 m/s, AND/OR moderate or severe prosthetic valve regurgitation)
Requiring repeat procedure (TAVI or SAVR)
Prosthetic valve endocarditis
Prosthetic valve thrombosis
Thrombo-embolic events (e.g. stroke)
VARC bleeding, unless clearly unrelated to valve therapy (e.g. trauma)</outcome>
      <timepoint>From device implant to completion of follow up at 5 years.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>New York Heart Association (NYHA) Functional classification of heart failure.</outcome>
      <timepoint>Change in NYHA class between baseline and 30 days, 6 months, 1, 2, 3, 4 and 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Six minute walk test (6MWT) - Distance in metres that the participant can walk in 6 minutes.</outcome>
      <timepoint>Change between baseline and 30 days, 6 months, 1, 2, 3, 4 and 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life Assessment. - Quality of life is quantified using the EQ-5D-5L questionnaire.</outcome>
      <timepoint>Change in Quality of Life from Baseline to 30 days, 6 months, 1, 2, 3, 4 and 5 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patient has signed the Patient Informed Consent prior to participating in the clinical
             investigation.

          -  Patient has been referred for a Portico Valve implant as per Heart Team decision.

          -  Patient has senile degenerative aortic stenosis with an initial valve area of less
             than (&lt;) 1.0 cm2 (or aortic valve area index less than or equal to (=) 0.6 cm2/m2) AND
             a mean transvalvular gradient greater than (&gt;) 40mmHg or jet velocity greater than (&gt;)
             4.0 m/s derived by resting echocardiogram [or dobutamine stress echocardiogram if
             subject has a left ventricular ejection fraction (LVEF) &lt; 50%]. (Baseline measurement
             taken by echo within 45 days of index procedure).

          -  Patient has a life expectancy more than (&gt;) 12 months.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Any case in which the Portico Valve would not be indicated for the patient as per
             current instructions for use (i.e any "off-label" use).

          -  Patient has any other than tricuspid valve.

          -  Patient has a prosthetic valve or ring in the aortic position.

          -  Patient needs a concomitant structural heart procedure.

          -  Patient needs the usage of an embolic protection device.

          -  Patient is unwilling or unable to comply with all clinical investigation-required
             follow-up evaluations.

          -  Patient is pregnant</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1050</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/08/2022</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>St Andrews Hospital - Adelaide</hospital>
    <hospital>Heart Care Partners-Wesley Hospital - Auchenflower</hospital>
    <hospital>The Prince Charles Hospital - Chermside</hospital>
    <hospital>Royal North Shore hospital - Leonards Hill</hospital>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <hospital>Royal Melbourne Hospital - City Campus - Parkville</hospital>
    <hospital>Fiona Stanley Hospital - Perth</hospital>
    <hospital>Royal North Shore Hospital - St Leonards</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <postcode> - Adelaide</postcode>
    <postcode> - Auchenflower</postcode>
    <postcode> - Chermside</postcode>
    <postcode> - Leonards Hill</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Parkville</postcode>
    <postcode> - Perth</postcode>
    <postcode> - St Leonards</postcode>
    <postcode> - Woolloongabba</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liege</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Middleheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Calgary</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Halifax</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Montreal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ottawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Saint John</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Torontp</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Vancouver</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Copenhagen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Nauheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bernau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bremen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dortmund</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Göttingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Jena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Karlsruhe</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munchen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Alessandria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Catania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Massa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Monza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Leeuwarden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>El Palmar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Zurich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Brighton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Morriston</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>St. Jude Medical</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Further assess the performance and safety profile of the commercially available Portico Valve
      implanted, using the Delivery System and the Loading System, in patients with severe
      symptomatic aortic stenosis.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01802788</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Lars Søndergaard, DMSc</name>
      <address>Rigshopitalet University Hospital, Copenhagen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Mariella Van Ransbeeck</name>
      <address />
      <phone>+322 774 68 29</phone>
      <fax />
      <email>mvanransbeeck@sjm.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>